HomeCompareDOCRF vs ARCC

DOCRF vs ARCC: Dividend Comparison 2026

DOCRF yields 9756.10% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DOCRF wins by $43230381229833840.00M in total portfolio value
10 years
DOCRF
DOCRF
● Live price
9756.10%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43230381229833840.00M
Annual income
$42,375,942,331,967,610,000,000.00
Full DOCRF calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — DOCRF vs ARCC

📍 DOCRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDOCRFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DOCRF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DOCRF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DOCRF
Annual income on $10K today (after 15% tax)
$829,268.29/yr
After 10yr DRIP, annual income (after tax)
$36,019,550,982,172,465,000,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, DOCRF beats the other by $36,019,550,982,172,465,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DOCRF + ARCC for your $10,000?

DOCRF: 50%ARCC: 50%
100% ARCC50/50100% DOCRF
Portfolio after 10yr
$21615190614916920.00M
Annual income
$21,187,971,165,983,804,000,000.00/yr
Blended yield
98.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

DOCRF
No analyst data
Altman Z
-7.4
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DOCRF buys
0
ARCC buys
0
No recent congressional trades found for DOCRF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDOCRFARCC
Forward yield9756.10%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$43230381229833840.00M$24.5K
Annual income after 10y$42,375,942,331,967,610,000,000.00$1.14
Total dividends collected$43173501257510792.00M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: DOCRF vs ARCC ($10,000, DRIP)

YearDOCRF PortfolioDOCRF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$986,310$975,609.76$11,373$532.74+$974.9KDOCRF
2$90,985,578$89,930,226.22$12,608$279.46+$90.97MDOCRF
3$7,850,557,226$7,753,202,657.96$13,809$142.90+$7850.54MDOCRF
4$633,609,188,528$625,209,092,296.54$15,042$72.20+$633609.17MDOCRF
5$47,836,734,147,594$47,158,772,315,868.44$16,341$36.27+$47836734.13MDOCRF
6$3,378,690,702,500,742$3,327,505,396,962,816.50$17,732$18.18+$3378690702.48MDOCRF
7$223,260,494,299,726,370$219,645,295,248,050,560.00$19,231$9.10+$223260494299.71MDOCRF
8$13,803,319,479,942,732,000$13,564,430,751,042,025,000.00$20,851$4.55+$13803319479942.71MDOCRF
9$798,541,026,043,208,800,000$783,771,474,199,670,000,000.00$22,605$2.28+$798541026043208.75MDOCRF
10$43,230,381,229,833,840,000,000$42,375,942,331,967,610,000,000.00$24,504$1.14+$43230381229833840.00MDOCRF

DOCRF vs ARCC: Complete Analysis 2026

DOCRFStock

CloudMD Software & Services Inc. operates as a healthcare technology company in North America. The company operates through three segments: Clinic Services & Pharmacies, Digital Health Services, and Enterprise Health Solutions. It offers enterprise health solutions, including mental health support, healthcare navigation, rehabilitation and assessments, education, and absence management and occupational health. The company also provides billing and electronic medical records solutions; MyHealthAccess, a patient portal that enables online appointment booking and virtual care visits; and Health and Wellness, a real time intervention and prevention platform, which enables an automated real time inquiry of disparate data sources in various domains, identify indicators, and compute risk scores. In addition, it offers iMD platform for peer-reviewed educational resources; telemedicine services; and VisionPros, an online vision care platform that provides contact lenses to customers. Further, the company operates a network of hybrid medical and rehabilitation clinics; and medical clinics for family practice and patient care on-site, as well as retails prescription drugs, over-the-counter drugs, and other front store items through two pharmacies. Additionally, it provides patient support programs that offers navigation and support for holistic disease management and clinical treatment outcomes; and pharmaceutical logistic services, including drug distribution and patient navigation assistance, as well as real-time universal disease management software. The company was formerly known as Premier Health Group Inc. and changed its name to CloudMD Software & Services Inc. in February 2020. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

Full DOCRF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this DOCRF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DOCRF vs SCHDDOCRF vs JEPIDOCRF vs ODOCRF vs KODOCRF vs MAINDOCRF vs HTGCDOCRF vs GBDCDOCRF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.